Sang-In Lee

Post‐infectious irritable bowel syndrome in patients with Shigella infection

Background and Aims: Bacterial gastroenteritis has been known as a risk factor of irritable bowel syndrome (IBS). Several risk factors of post‐infectious IBS (PI‐IBS) have been documented. The aims of this study were to verify the role of bacterial gastroenteritis in the development of IBS and the risk factors for the development of PI‐IBS. The clinical course of PI‐IBS was also investigated.

Efficacy of low‐dose clarithromycin triple therapy and tinidazole‐containing triple therapy for Helicobacter pylori eradication

Proton pump inhibitor‐based triple therapies are recommended as the first‐line treatment for Helicobacter pylori eradication.

A double‐blind, randomized, parallel group study of omeprazole and ranitidine in Korean patients with gastric ulcer

Abstract The efficacy of the proton pump inhibitor omeprazole, 20 mg every morning, was compared with that of the H2‐receptor antagonist ranitidine, 150 mg every morning and at bedtime, in a double‐blind randomized parallel group study in 250 patients with gastric or prepyloric uicers. At both 4 and 8 weeks, significantly more patients had healed ulcers in the omeprazole group than the ranitidine group, whether the results were analysed on a per‐protocol or an intention‐to‐treat basis. At 4 weeks, 74% of patients in the omeprazole group were healed compared with 51% in the ranitidine group (P= 0.001), and at 8 weeks the corresponding values were 99 and 82% (P= 0.001, per‐protocol cohort). Omeprazole treatment and small ulcer size significantly increased the probability of healing, but smoking had no significant effect. Patients in the omeprazole group had significantly fewer occurrences of daytime epigastric pain during the first 4 weeks than the ranitidine group (P= 0.0037), as shown by their diary cards. Both treatments were well tolerated.